1. Impact of High-Risk Cytogenetics and Achievement of Molecular Remission on Long- Term Freedom from Disease after Autologous–Allogeneic Tandem Transplantation in Patients with Multiple Myeloma 
Nicolaus Kröger, Anita Badbaran, Tatjana Zabelina, Francis Ayuk, Christine Wolschke, Haefaa Alchalby, Evgeny Klyuchnikov, Djordje Atanackovic, Georgia Schilling, Timon Hansen, Sabine Schwarz, Marion Heinzelmann, Silke Zeschke, Ulrike Bacher, Thomas Stübig, Boris Fehse, Axel R. Zander 
Biology of Blood and Marrow Transplantation 
Volume 19, Issue 3, Pages (March 2013)
DOI: /j.bbmt
Copyright © Terms and Conditions

2. Figure 1
mCR after Auto–Allo Tandem SCT in MM. ASO indicates allele-specific oligonucleotide; PCC, plasma cell chimerism. ∗Five patients with high-risk cytogenetics. †One patient with high-risk cytogenetics.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © Terms and Conditions

3. Figure 2
Achievement of mCR after auto–allo tandem SCT. Patients 1-15 achieved a mixed mCR; patients 15-30, a sustained mCR. REZ, relapse; ○, MRD-negative; ●, MRD-positive.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © Terms and Conditions

4. Figure 3
OS (A) and PFS (B) after auto–allo tandem SCT according to achievement of mCR.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © Terms and Conditions

5. Figure 4
Cumulative incidence of relapse after auto–allo tandem SCT according to achievement of mCR.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © Terms and Conditions